Carl LeBel (Chief Development Officer of Frequency) revealed on the Tinnitus Talk Podcast that several patients in the Phase I/II study reported "improved" tinnitus to their ENTs. How much improvement wasn't measured, but it's one of the reasons they're testing for tinnitus in the phase 2a study.
Otonomy's OTO-413 drug (to fix the ribbon synapses in the cochlea) also seems really promising (results are due out next month). However, for their phase I/II study they're not testing for tinnitus and are actually excluding patients with "bothersome tinnitus". I'm hoping they see the same thing as Frequency and that some patients report improved tinnitus. These two drugs together (regrowing hair cells and ribbon synapses) seem like they could be a good one-two punch against hearing loss and tinnitus.
Otonomy's OTO-413 drug (to fix the ribbon synapses in the cochlea) also seems really promising (results are due out next month). However, for their phase I/II study they're not testing for tinnitus and are actually excluding patients with "bothersome tinnitus". I'm hoping they see the same thing as Frequency and that some patients report improved tinnitus. These two drugs together (regrowing hair cells and ribbon synapses) seem like they could be a good one-two punch against hearing loss and tinnitus.